Updated analysis of CALGB (Alliance) 100104
Mené sur 460 patients atteints d'un myélome multiple, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du lénalidomide en traitement d'entretien après une greffe autologue de cellules souches (durée médiane de suivi : 91 mois)
The Article by Sarah Holstein and colleagues1 established a new benchmark for survival of 9·5 years for patients with multiple myeloma who were 70 years or younger, candidates for transplantation (without comorbidities), and receiving maintenance treatment with the immunomodulating drug lenalidomide. After a very long median follow-up (91 months), time to progression was significantly longer in the lenalidomide group than in the placebo group (57·3 months vs 28·9 months; hazard ratio 0·57, 95% CI 0·46–0·71; p<0·0001).
The Lancet Haematology , commentaire, 2016